Price
No data yet.
Social Signal Score
Company Profile
- Sector
- Financial Services
- Industry
- Asset Management
- Beta
- 0.56
- Country
- US
Quote
Valuation & Ratios
Returns & Efficiency
Valuation
BBHhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
90-25.00%Social Signal Score
Mentions (3)
- Newszacks.com·17d ago·Negative
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.
View source ↗ - Newszacks.com·22d ago·Neutral
Should You Invest in the VanEck Biotech ETF (BBH)? Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20, 2011.
View source ↗ - Newsseekingalpha.com·45d ago·Positive
BBH: Biotech's Next Growth Cycle Is Just Getting Started VanEck Biotech ETF (BBH) is a Buy, offering concentrated exposure to leading biotech firms entering a new growth cycle. BBH's top holdings—Amgen, Gilead, and Vertex—drive capital appreciation through diversified pipelines, strong cash flows, and expansion into new therapeutic areas. Despite a higher expense ratio and low yield, BBH's risk-reward profile is attractive given enduring demand and robust product pipelines.
View source ↗
Congress trades
- Thomas Suozzihouse · NY03 · disclosed May 20, 2022 (77d later)Sell$50,001 - $100,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Feb 1, 2022 (4d later)Sell$1,001 - $15,000
- Donald Sternoff Beyerhouse · VA08 · disclosed Jan 1, 2022 (10d later)Buy$1,001 - $15,000
- Thomas Suozzihouse · NY03 · disclosed Nov 5, 2021 (16d later)Buy$50,001 - $100,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.